drugset / Trial / NCT00831766
Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)
Phase 1/2
Completed
51 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Celgene Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to: * Test the safety of the research study drug, lenalidomide, when given with Idarubicin and Cytarabine * See how many respond to combination treatment with lenalidomide, Idarubicin and Cytarabine * See how long people respond to this combination therapy * See how long people live after being treated with this combination of drugs
Timeline
- Start
- 2009-06-25
- Primary completion
- 2015-02-17
- Completion
- 2020-11-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 200 mg/m2 | — |
| Subject | Idarubicin | Small molecule | 12 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 5 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Subject | Lenalidomide | Other / unclassified | 20 mg | — |
| Subject | Lenalidomide | Other / unclassified | 25 mg | — |